NEW YORK, Oct. 9, 2024 /PRNewswire-PRWeb/ -- Kyowa Hakko USA, Inc., under the Cognizin® brand, is proud to announce the granting of a method-of-use patent for citicoline or its salts. The ...

3, 2024 /PRNewswire-PRWeb/ -- Kyowa Hakko USA, a global leader in the health ... A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated ...

This includes Cognizin citicoline from Kyowa Hakko for brain health support, enfinity Paraxanthine from TSI Group for steady energy, goBHB Ketones from Ketone Labs for improved endurance, MitoPrime ...

AstraZeneca(AZ) is to work with Kyowa Hakko Kirin on a phase I/Ib immuno-oncology study that will evaluate two separate combinations of three investigational compounds in multiple solid tumours.